| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044123089 |
| P356 | DOI | 10.1007/S00280-006-0291-9 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s00280-006-0291-9 |
| P698 | PubMed publication ID | 16906425 |
| P50 | author | Wolfgang Sadee | Q57715733 |
| P2093 | author name string | Ying Huang | |
| Xincheng Zheng | |||
| Ping Wen | |||
| Duxin Sun | |||
| Zunyan Dai | |||
| Lanyan Fang | |||
| Xianhua Cao | |||
| Seth Gibbs | |||
| P2860 | cites work | Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. | Q34117304 |
| Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. | Q35746400 | ||
| The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase | Q36292800 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| daunorubicin | Q411659 | ||
| P304 | page(s) | 495-505 | |
| P577 | publication date | 2006-08-12 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia | |
| P478 | volume | 59 |
| Q33565915 | 1,25-dihydroxyvitamin D regulation of glucose metabolism in Harvey-ras transformed MCF10A human breast epithelial cells |
| Q92442029 | 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents |
| Q90264025 | A Novel Drug Resistance Mechanism: Genetic Loss of Xeroderma Pigmentosum Complementation Group C (XPC) Enhances Glycolysis-Mediated Drug Resistance in DLD-1 Colon Cancer Cells |
| Q36413261 | A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models |
| Q35404082 | A metabolomic approach to identifying platinum resistance in ovarian cancer |
| Q27939281 | A molecular switch on an arrestin-like protein relays glucose signaling to transporter endocytosis |
| Q38998413 | AMPK and Cancer |
| Q36608747 | Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention |
| Q35742791 | Altered glucose metabolism in Harvey-ras transformed MCF10A cells |
| Q39064468 | Anticancer agents interacting with membrane glucose transporters |
| Q36452381 | Anticancer agents that counteract tumor glycolysis. |
| Q61818568 | Biochemical Basis of Anti-Cancer-Effects of Phloretin-A Natural Dihydrochalcone |
| Q33625341 | Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model |
| Q39262718 | Citrate kills tumor cells through activation of apical caspases |
| Q52721498 | Current Opinions on Chemoresistance: An Overview. |
| Q36032683 | Development of a novel class of glucose transporter inhibitors |
| Q90578498 | Discovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D Microarrays |
| Q42005150 | Effects of antibiotic antitumor drugs on nucleotide levels in cultured tumor cells: an exploratory method to distinguish the mechanisms of antitumor drug action based on targeted metabolomics |
| Q46521228 | Efficacy of pentavalent antimony, amphotericin B, and miltefosine in Leishmania amazonensis-infected macrophages under normoxic and hypoxic conditions |
| Q37137623 | Emerging metabolic targets in the therapy of hematological malignancies |
| Q38722232 | Expression of HMGB2 indicates worse survival of patients and is required for the maintenance of Warburg effect in pancreatic cancer |
| Q34657372 | Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. |
| Q46411715 | Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. |
| Q55396364 | Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. |
| Q35828442 | Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models. |
| Q37623840 | GLUT1 as a therapeutic target in hepatocellular carcinoma |
| Q92610269 | GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome |
| Q37347110 | Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells |
| Q22252348 | How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models |
| Q49725890 | Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment. |
| Q34671206 | Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). |
| Q38836365 | Icaritin inhibits the invasion and epithelial-to-mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/AKt/HIF-1α signalling |
| Q35595838 | In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy. |
| Q54978523 | Inhibition of Glycolysis and Glutaminolysis: Emerging Drug Discovery Approach to Combat Cancer. |
| Q39160723 | Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin |
| Q38840489 | Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics |
| Q58573448 | Leptin and its receptor in glucose metabolism of T-cell lymphoma |
| Q39265746 | Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. |
| Q53694850 | Metabolic Features of Multiple Myeloma. |
| Q90642651 | Metabolic Plasticity in Chemotherapy Resistance |
| Q89622373 | Metabolic Symbiosis in Chemoresistance: Refocusing the Role of Aerobic Glycolysis |
| Q37908233 | Metabolic alterations in cancer cells and therapeutic implications |
| Q38181405 | Metabolic implication of tumor:stroma crosstalk in breast cancer |
| Q35612105 | Metabolic signature identifies novel targets for drug resistance in multiple myeloma |
| Q38741503 | Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy |
| Q35674921 | Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA |
| Q36010195 | Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy |
| Q34332053 | Osteopontin upregulates the expression of glucose transporters in osteosarcoma cells |
| Q38952954 | Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism |
| Q42071893 | PTEN deficiency and mutant p53 confer glucose-addiction to thyroid cancer cells: impact of glucose depletion on cell proliferation, cell survival, autophagy and cell migration. |
| Q39201094 | PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells |
| Q26778007 | Pathophysiological mechanisms of death resistance in colorectal carcinoma |
| Q38362491 | Principles in the design of ligand-targeted cancer therapeutics and imaging agents. |
| Q26796405 | Progress toward overcoming hypoxia-induced resistance to solid tumor therapy |
| Q35852614 | Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. |
| Q64946449 | Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis. |
| Q33356241 | Selective inhibition of yeast regulons by daunorubicin: a transcriptome-wide analysis |
| Q50050739 | Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SHSY-5Y by inhibiting PI3K/Akt-dependent glycolysis. |
| Q39879662 | Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy |
| Q36951663 | Single Cell "Glucose Nanosensor" Verifies Elevated Glucose Levels in Individual Cancer Cells |
| Q36815271 | Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance |
| Q39190194 | Strategies to Target Glucose Metabolism in Tumor Microenvironment on Cancer by Flavonoids |
| Q38889490 | Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways |
| Q24596727 | Targeting cellular metabolism to improve cancer therapeutics |
| Q37446828 | Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine |
| Q27025144 | Targeting glycogen metabolism in bladder cancer |
| Q39418495 | Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin |
| Q37714309 | Targeting metabolic transformation for cancer therapy. |
| Q38058130 | Targeting the latest hallmark of cancer: another attempt at 'magic bullet' drugs targeting cancers' metabolic phenotype |
| Q26770007 | The Warburg effect and drug resistance |
| Q27025749 | The Warburg effect revisited--lesson from the Sertoli cell |
| Q38623792 | Trienamine catalyzed asymmetric synthesis and biological investigation of a cytochalasin B-inspired compound collection |
| Q34204238 | Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters |
| Q46791877 | Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1α and glycolysis, by inhibiting PI3K/Akt signaling pathway |
| Q37412531 | ZnCl2 sustains the adriamycin-induced cell death inhibited by high glucose. |
| Q55464273 | [Advances in the research of glycolysis and lung cancer]. |
Search more.